recentpopularlog in

joeybaker : healthcaremalfeasance   100

« earlier  
The more drugmakers wowed doctors with gifts and lunches, the more people died of drug overdoses, study shows
“Our findings suggest that direct-to-physician opioid marketing may counter current national efforts to reduce the number of opioids prescribed.”
healthcareMalfeasance  healthcareCorruption  corporateCorruption 
january 2019 by joeybaker
The United States, on a per capita basis, spends much more on health care than other developed countries; the chief reason is not greater health care utilization, but higher prices, according to a new study from Johns Hopkins.
The United States, on a per capita basis, spends much more on health care than other developed countries; the chief reason is not greater health care utilization, but higher prices, according to a stu
healthcareMalfeasance  casteingTheLowerClass  casteingTheMiddleClass 
january 2019 by joeybaker
The average outpatient visit in the US costs nearly $500, according to a new study. In addition, the average inpatient stay had a price tag in 2016 of more than $22,000. Both underscore a common understanding in the health profession: The US exceeds every
The average outpatient visit in the United States costs nearly $500, according to a new scientific study. In addition, the average inpatient stay had a price tag in 2016 of more than $22,000. Both of these dollar amounts underscore a common understanding in the health profession: The US exceeds every other nation in total health care costs.
healthcareMalfeasance  governmentIncompetence 
december 2018 by joeybaker
Study shows that insulin prices could be much lower and drug makers would still make healthy profits
Introduction High prices for insulin pose a barrier to treatment for people living with diabetes, with an estimated 50% of 100 million patients needing insulin lacking reliable access. As insulin analogues replace regular human insulin (RHI) globally, their relative prices will become increasingly important. Three originator companies control 96% of the global insulin market, and few biosimilar insulins are available. We estimated the price reductions that could be achieved if numerous biosimilar manufacturers entered the insulin market. Methods Data on the price of active pharmaceutical ingredient (API) exported from India were retrieved from an online customs database. Manufacturers of insulins were contacted for price quotes. Where market API prices could not be identified, prices were estimated based on comparison of similarity, in terms of manufacturing process, with APIs for which prices were available. Potential biosimilar prices were estimated by adding costs of excipients, formulation, transport, dev
corporateCorruption  healthcareMalfeasance  casteingTheLowerClass  kleptocracy 
september 2018 by joeybaker
For-profit hospitals correlated with higher readmission rates - Patients who receive care in a for-profit hospital are more likely to be readmitted than those who receive care in nonprofit or public hospitals, according to a new study.
Patients who receive care in a for-profit hospital are more likely to be readmitted than those who receive care in nonprofit or public hospitals, according to a new study published by University of Illinois at Chicago researchers.
healthcareMalfeasance  healthcareIncompetence 
september 2018 by joeybaker
Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative
Exclusive: 71 million people stand to benefit from reduced price treatment for virus which can lead to liver cirrhosis, cancer and death
healthcareMalfeasance  intellectualProperty 
april 2018 by joeybaker
Cancer drug price rises 15-fold as owner raises cost for ninth time in four years
The cost of a vital cancer drug has gone up 15-fold in four years after its new owner hiked prices on nine separate occasions. Lomustine has been used to treat brain tumours, lung cancer and Hodgkin’s lymphoma for more than 40 years but is now seen by some patients as too expensive. In 2013, production of the drug, which was previously called CeeNU, passed from pharma giant Bristol-Myers Squibb to a Miami-based startup called NextSource Biotechnology.
corporateCorruption  healthcareMalfeasance 
march 2018 by joeybaker
« earlier      
per page:    204080120160

Copy this bookmark:





to read